United Therapeutics (UTHR) Interest Coverage Ratio Growth (3y) (2012 - 2026)
Powered by 
Analysis
United Therapeutics (UTHR) Interest Coverage Ratio Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.24 Bn | 623.49 Bn | 17.26 Bn | -1.75% |
| 2 | AbbVie | 443.24 Bn | 436.67 Bn | 12.70 Bn | - |
| 3 | Merck | 364.92 Bn | 357.78 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.33 Bn | 258.64 Bn | 11.24 Bn | -7.51% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.37 Bn | 44.99 Bn | 10.79 Bn | -26.54% |
| 7 | Revolution Medicines | 44.03 Bn | 44.03 Bn | - | - |
| 8 | Incyte | 25.35 Bn | 20.82 Bn | 1.57 Bn | 59.44% |
| 9 | United Therapeutics | 21.58 Bn | 18.92 Bn | 683.80 Mn | 75.30% |
| 10 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | -2.64% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 75.30% |
| Mar 31, 2026 | 74.02% |
| Dec 31, 2025 | 100.50% |
| Sep 30, 2025 | 55.92% |
| Jun 30, 2025 | 15.33% |
| Mar 31, 2025 | 0.80% |
| Dec 31, 2024 | 7.82% |
| Sep 30, 2024 | -11.92% |
| Jun 30, 2024 | -16.45% |
| Mar 31, 2024 | 57.43% |
| Dec 31, 2023 | 8.18% |
| Sep 30, 2023 | -22.55% |
| Jun 30, 2023 | -5.50% |
| Mar 31, 2023 | 0.46% |
| Dec 31, 2022 | 31.00% |
| Sep 30, 2022 | 29.65% |
| Jun 30, 2022 | 21.50% |
| Mar 31, 2022 | 43.62% |
| Dec 31, 2021 | 5.71% |
| Sep 30, 2021 | 10.86% |